Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:28:26.054Z.
Consensus retrieved: 2026-10-06T16:38:12.771Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:28:26.054Z.
Quote observation: 2026-10-06T18:24:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
Forward PE Ratio (N/A) = Dated Quote Price ($17.59) / Consensus Forward EPS ($-4.43)
FORWARD PE RATIO
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$941.60M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $941.60M | N/A |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | N/A |
| CeriBell, Inc. (CBLL)vs › | $935.90M | N/A |
| Savara Inc. (SVRA)vs › | $953.94M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $930.32M | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $969.98M | N/A |
| HealthStream, Inc. (HSTM)vs › | $912.83M | 42.34 |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | N/A |
| Bioventus Inc. (BVS)vs › | $899.69M | 17.05 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $17.59, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.43 | $-5.18 – $-4.01 | 5 | n/m |
| 2027-12-31 | $-2.58 | $-3.03 – $-2.17 | 5 | n/m |
| 2028-12-31 | $-2.64 | $-3.20 – $-2.10 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
